Amgen Inc. (NASDAQ:AMGN) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 8.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 419,178 shares of the medical research company’s stock after selling 36,427 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Amgen worth $109,255,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AMGN. Twelve Points Wealth Management LLC lifted its stake in Amgen by 73.8% in the 4th quarter. Twelve Points Wealth Management LLC now owns 3,246 shares of the medical research company’s stock worth $846,000 after purchasing an additional 1,378 shares in the last quarter. Capital Investment Counsel LLC lifted its stake in Amgen by 2.4% in the 4th quarter. Capital Investment Counsel LLC now owns 18,618 shares of the medical research company’s stock worth $4,853,000 after purchasing an additional 431 shares in the last quarter. BSW Wealth Partners lifted its stake in Amgen by 3.5% in the 4th quarter. BSW Wealth Partners now owns 2,371 shares of the medical research company’s stock worth $618,000 after purchasing an additional 81 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Amgen by 1.6% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,382 shares of the medical research company’s stock worth $1,142,000 after purchasing an additional 67 shares in the last quarter. Finally, Tamar Securities LLC lifted its stake in Amgen by 8.6% in the 4th quarter. Tamar Securities LLC now owns 57,088 shares of the medical research company’s stock worth $14,879,000 after purchasing an additional 4,537 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ:AMGN opened at $280.30 on Wednesday. The company has a fifty day simple moving average of $271.48 and a two-hundred day simple moving average of $305.15. The company has a market cap of $150.67 billion, a price-to-earnings ratio of 35.89, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.96 earnings per share. As a group, equities analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.40%. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is presently 115.24%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AMGN. Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler reduced their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.